Assessing the Adverse Events From Lutetium Lu 177 Dotatate for Advanced Midgut Neuroendocrine Tumors
Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses some of the adverse events patients experienced during the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
Pharmacy Times interviewed Jonathan Strosberg, MD, a professor of medical oncology, section head of the Neuroendocrine Tumor Program, and vice president of Medical Oncology at the Moffitt Cancer Center, on his presentation at the 2021 ASCO Annual Meeting about the NETTER-1 phase 3 trial of lutetium Lu 177 dotatate (Lutathera, Novartis) for midgut neuroendocrine tumors.
During the discussion, Strosberg detailed some of the adverse events experienced by patients with advanced midgut neuroendocrine tumors when treated with lutetium Lu 177 dotatate during the phase 3 trial. Strosberg also noted how patients were able to handle the treatment during the trial as well.
